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Elevated serum KL-6 in pediatric asthma exacerbation: a proof of alveolar injury 
 
INTRODUCTION 
One of the most popular chronic diseases, 
particularly in children, is asthma. This disease is 
defined to be a complicated inflammatory disorder 
in which the patient suffers from chronic and 
persistent inflammation of the airways.1,2 In 2014, 
the number of patients with this disease reached 
300 million people worldwide. Asthma is more 
frequent in the developing countries than the 
developed ones.3 The frequency of this disease is 
increasing sharply in spite of the significant 
progress in pharmacological therapy.  Several 
previous studies in literature investigated the 
mechanisms underlying asthma pathogenesis, 
recognizing the epithelial cell injury to be a major 
cause of asthma.4 
The sialylated glycoprotein Krebs von den 
Lungen-6 (KL-6), one of the lung epithelium-
specific proteins, has been studied and recognized 
as a significant biomarker that directly associates 
with the pathogenesis of interstitial lung disease 
(ILD). It is indicative of the extent of damage and 
regeneration of type II pneumocytes.5 In addition, 
high serum KL-6 levels have been recently 
presented by many studies to be a severity indicator 
of systemic sclerosis disease which is measured 
through pulmonary function test (PFT) as well as a 
predictor of its early progression.6,7 Kl-6 splits off 
the S-S bond close to the epithelial membrane 
surface. Then, it becomes distributed in pulmonary 
epithelial lining fluid.8 The expression of this 
glycoprotein   always takes place on alveolar type 2 
cells in the lung. The rate of KL-6 expression is 
higher in the proliferating, regenerating, or injured 
type 2 cells compared to the normal ones.9 
Some studies reported the correlation between 
KL-6 plasma levels and the indices of alveolar 
capillary permeability; this suggests an association 
between serum KL-6 and alveolar epithelial barrier 
dysfunction.10,11 Moreover, the circulating levels of 
this protein have been recognized and used as a 
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diagnostic as well as prognostic tool in a variety of 
interstitial pneumonitis, sarcoidosis, and alveolar 
proteinosis. However, KL-6 was not studied 
extensively as a biomarker for pediatric asthma.12  
The aim of this work is to investigate the degree 
of alveolar damage in asthmatic children with acute 




This controlled cross sectional study included 50 
patients with acute asthma exacerbation who were 
diagnosed as per the GINA guidelines’ definition 13 
and 50 age- and sex-matched healthy children who 
have neither history nor symptoms of bronchial 
asthma, pulmonary diseases, other allergies or 
atopic dermatitis nor first-degree relatives suffering 
from bronchial asthma or atopic dermatitis as a 
control group.  
The aim and nature of the study were explained 
to all the participants’ parents/care givers. and an 
informed consent was obtained from them before 
children enrollment. The ethical committee of the 
Pediatrics’ Department, Faculty of Medicine, Cairo 
University, approved the work. This study 
conforms to the provisions of the Declaration of 
Helsinki in 1964 and its later amendments or 
comparable ethical standards. 
Exclusion criteria of this study were acute 
respiratory distress that necessitates prompt 
intervention and latent pulmonary diseases 
(including but not limited to cystic fibrosis, 
congenital heart disease, congenital respiratory 
disease, and thoracic deformity). In addition, 
children of age more than 18 years or less than 6 
years were excluded (as Spirometry cannot be 
performed for the children less than 6 years) and to 
avoid cases of non-asthmatic early life wheeze 
Thorough history taking and physical examination 
were conducted for all patients upon study 
inclusion, including respiratory symptoms, other 
atopic manifestations, and disease severity. 
 
Spirometry (Master Scope-PC) was done for all 
participants. Measurements included forced 
expiratory volume in one second (FEV1), forced 
vital capacity (FVC), FEV1/FVC%, and FEF25-
75%. Readings were correlated with age, sex, and 
the standing height of children. Results were 
expressed as percentages of predicted values for sex 
and height. Prior to each testing session, calibration 
was done on site according to the manufacturer’s 
instructions. Three technically accepted maneuvers 
at least were obtained with less than 0.15 L 
variability for FEV1 and FVC between the highest 
and second highest result.14,15  
 
Measurement of serum Kerbs von Lungren 6 
antigen: Serum Kerbs von Lungren 6 antigen (KL-
6) levels were estimated by Enzyme Linked 
Immunosorbent Assay (ELISA) kit (Bioassay 
technology laboratory Cat. No E1980Hu) that uses 
a double-antibody sandwich to assay the KL-6 level 
in blood samples. The results were calculated by the 
straight line regression equation of the standard 
curve of the standard density and the optical density 
(OD) values of the provided standard and its serial 
dilutions. With the sample OD value in the 
equation, the tested sample serum concentration of 
KL-6 was calculated.  
Total serum IgE level was measured via the 
electrochemiluminescence technology using the 
cobase e 411 immunoassay analyzer (Roche, USA) 
according to the manufacturer’s instructions. 
 
Statistical analysis 
Data were coded and entered using the statistical 
package for Social Sciences (SPSS) version 25 
(IBM Corp., Armonk, NY, USA).  Data were 
summarized using mean, standard deviation, 
median, minimum and maximum in quantitative 
data. Comparisons between quantitative variables 
were done using the non-parametric Mann-Whitney 
test.16 P-values less than 0.05 were considered as 




A total number of 100 participants were 
recruited in this study. The case group included 35 
(70%) males and 15 (30%) females with mean age 
of 10.76 ±1.9 years. Forty-seven patients (94%) had 
a positive family history of bronchial asthma and 32 
patients (64%) had atopic manifestations such as 
conjunctivitis, allergic rhinitis, or skin allergy. The 
patients’ demographic data are listed in Table (1). 
Table (2) demonstrates the mean spirometric 
parameters (the percentage predicted) in studied 
participants which were statistically lower in 
patients than in controls. These statistical data were 
highly significant. Serum KL-6 levels were 
significantly higher in cases than in controls. The 
mean serum KL-6 level in cases was more than 
double the mean level in controls (115.79 vs 55.64) 
table (4), figure (1). 
No correlation was observed between KL-6 
serum level and age, family history of asthma, 
seasonal variation, or atopic manifestation among 
the cases. Serum total IgE levels were significantly 
KL-6 in pediatric asthma 
37 
 
higher in cases compared to controls (P<0.05). The 
cases studied during acute exacerbation had asthma 
for a mean duration of 4.21 years. No significant 
correlation was found between the duration of 
asthma and KL-6 level. 
 
Table 1. Demographic data of the studied sample. 
 Cases  Controls  
Age (years) 10.76+-1.9 10.12+-2.3 
Sex (male %) 35(70%) 37 (74%) 
Seasonal manifestation 30 (78%) - 
Atopic manifestations 32 (64%) - 
Urban residence 41 (82%) 40 (80%) 
Family history of asthma 47 (94%) 1 (2%) 
Family history of atopy 38 (76%) 2 (4%) 
Mean duration of asthma (years) 4.21 - 
Total 50 50 
 
Table 2. Mean total IgE level and PFT in patients compared to controls. 
 Cases Controls P value 
IgE (IU/ml) mean+-SD 745.12+-137 44.64+-31 P<0.05  
FEV1 (% predicted) 70.51+-11.3 98.87+-3.21 P<0.001 
FVC (% predicted) 87.40+-4.95 100.5+-3.75 P<0.001 
FEV1/FVC (% predicted) 73.59+-11.28 96.12+-2.54 P<0.001 
FEF 25-75% (% predicted) 63.12+-9.8 95+-4.12 P<0.001 
Total 50 50 - 
FEF: Forced Expiratory Flow, FEV1: Forced Expiratory Volume in one second, FVC: Forced Vital capacity,  IgE: Immunoglobulin 
E. 
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Figure 1. Comparison between serum KL-6 level in asthmatic patients during acute 
exacerbation and normal controls. P value <0.001. 
 




Previously, it was believed that the primary cellular 
source of KL-6 is type II pneumocytes 11 and that 
KL-6 concentration is extremely high in epithelial 
lining fluid.17,18 Therefore, the increase in 
circulating KL-6 levels in interstitial pneumonitis 
has been suggested to be attributed to an increase in 
KL-6 production by alveolar type II pneumocytes 
regeneration and/or an enhanced permeability 
taking place as a result of the air–blood barrier 
destruction in the affected lungs.19 Recent studies 
have presented the KL-6 as a potent pro-
proliferative and antiapoptotic agent upon lung 
fibroblasts.9,10 
Previous reports on adult asthmatic patients 
showed no significant increase in serum KL-6 
levels.18,20  However, our study on children revealed 
a statistically significant elevation of KL-6 serum 
levels in acute asthma flare cases compared to 
controls. This may indicate that serum KL-6 is a 
sensitive marker of lung damage in children. 
The elevation of KL-6 serum levels takes place 
in various interstitial lung diseases; these elevated 
levels are associated with alveolar epithelial cell 
damage. There is an association between serum 
KL-6 concentrations and alveolar-epithelial barrier 
dysfunction as they were reported to have a 
correlation with the indices of alveolar-capillary 
permeability.21 In the current study, alveolar injury 
was observed in asthmatic patients with acute 
exacerbation; this was indicated by higher KL-6 
levels compared to normal controls. The increased 
KL-6 levels in some of our patients, not all of them, 
indicate the possibility of mild alveolar epithelial 
damage.  
Bronchiolar epithelial cells and bronchial serous 
gland cells could be other sources of KL-6 in the 
bronchial lumen. However, the alveolar-capillary 
barrier has to be highly permeable to allow for 
increased serum KL-6 levels in asthma.22 Therefore, 
a degree of alveolar damage must be present in the 
cases with elevated serum concentrations of KL-6.9   
Thus, our results positively suggest that 
asthmatic children suffer from alveolar damage. 
Further studies to prove the correlation between 
KL-6 and various degrees of asthma severity could 
make KL-6 a reliable simple non-invasive tool for 
identification of patients in need for hospital 
admission. In the current work, we studied the 
degree of alveolar damage associated with the air 
way obstruction in pediatric asthmatic patients with 
acute exacerbation by measuring the serum level of 
KL-6 as a trial for saving the financial and medical 
burden by differentiating between patients who 
need intensive medical care by hospital admission 
and those who can be managed properly in the 
outpatient clinic.  
To our best knowledge, serum KL-6 level in 
asthmatic children has been investigated in only one 
previous study.23 If these findings are extrapolated 
on younger patients where PFT can be difficult to 
perform or not available in all health care facilities, 
KL-6 serum level would be a simple and practical 
measure to identify asthma severity.   
 
CONCLUSION 
Measuring plasma KL-6 levels in pediatric asthma 
patients may be a useful diagnostic tool for 
detecting and monitoring the severity of airway 
inflammation. The use of serum KL-6 alone 
enabled us to differentiate between asthmatic 
patients in exacerbation and healthy controls. In this 
context, screening of asthmatic children for KL-6 
may be a practical tool to identify patients at risk 
for acute exacerbation. The findings are indeed 
limited by the sample size. 
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